Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research Report) and Bright Health Group (BHG – Research Report).
Perspective Therapeutics (CATX)
In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Perspective Therapeutics, with a price target of $1.20. The company’s shares closed last Thursday at $0.47.
According to TipRanks.com, Jones is a 3-star analyst with an average return of
Currently, the analyst consensus on Perspective Therapeutics is a Moderate Buy with an average price target of $1.20.
See Insiders’ Hot Stocks on TipRanks >>
Bright Health Group (BHG)
In a report released today, Ricky Goldwasser from Morgan Stanley maintained a Sell rating on Bright Health Group, with a price target of $160.00. The company’s shares closed last Thursday at $0.18.
According to TipRanks.com, Goldwasser is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bright Health Group with a $33.20 average price target, implying a 18914.9% upside from current levels. In a report issued on May 9, Bank of America Securities also reiterated a Sell rating on the stock with a $0.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CATX:
- Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
- Perspective Therapeutics Announces Changes to the Board of Directors
- Is ISR a Buy, Before Earnings?
- Perspective Therapeutics appoints Andrew Bright as EVP, brachytherapy
- Perspective Therapeutics management to meet virtually with Oppenheimer
